908 Devices (908 Devices) Cash And Cash Equivalents : $104.60 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is 908 Devices Cash And Cash Equivalents?

908 Devices's quarterly cash and cash equivalents increased from Sep. 2023 ($118.21 Mil) to Dec. 2023 ($121.04 Mil) but then stayed the same from Dec. 2023 ($121.04 Mil) to Mar. 2024 ($104.60 Mil).

908 Devices's annual cash and cash equivalents declined from Dec. 2021 ($224.07 Mil) to Dec. 2022 ($188.42 Mil) and declined from Dec. 2022 ($188.42 Mil) to Dec. 2023 ($121.04 Mil).

908 Devices Cash And Cash Equivalents Historical Data

The historical data trend for 908 Devices's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

908 Devices Cash And Cash Equivalents Chart

908 Devices Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

17.91

159.23

224.07

188.42

121.04

908 Devices Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															161.21	133.00	118.21	121.04	104.60

908 Devices Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

908 Devices (NAS:MASS) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

908 Devices Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of 908 Devices's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

908 Devices (908 Devices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » 908 Devices Inc (NAS:MASS) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

645 Summer Street, Boston, MA, USA, 02210

Website

https://www.908devices.com

908 Devices Inc manufactures medical devices. It has developed an innovative suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

Executives

Griffith Joseph H. Iv	officer: Chief Financial Officer	68 ELM STREET, HOPKINTON MA 01748
Christopher D. Brown	officer: Chief Technology Officer	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Kevin J. Knopp	director, officer: President and CEO	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michael S. Turner	officer: VP, General Counsel	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Maura Fitzpatrick	officer: VP, Product Management & Mktg	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Mark Spoto	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Michele Fournier	officer: Chief People Officer	908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Trent A. Basarsky	officer: Vice President, Commercial	C/O PROTEINSIMPLE, 3040 OAKMEAD VILLAGE DRIVE, SANTA CLARA CA 95051
John Kenneweg	officer: Vice President, Government	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Anthony Hunt	director	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Marcia Eisenberg	director	C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Fenel M Eloi	director	C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Keith Crandell	director, 10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631